Clinical trials: AIDS
HIV Infections
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Pre-exposure prophylaxis (PrEP) is a method of preventing HIV infection through the use of antiretroviral (ARV) medications before exposure to HIV.
- Trial name
- ADAPT (NCT01327651)
- Testing
- Daily dosing, Time-driven dosing, Event-driven dosing
- Where
- 3 sites in United States, South Africa and 1 more
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
HIV Infections
Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV
The purpose of this study is to compare plasma and intracellular pharmacokinetic parameters of raltegravir 800 mg administered once daily in HIV infected patients.
- Trial name
- NCT00995241
- Testing
- Raltegravir
- Where
- 2 sites in Spain
- Volunteers
- 5 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV
Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
HIV positive pregnant women who receive potent combination antiretroviral therapy over at least the last trimester of pregnancy, and who have proper obstetric interventions and are able to avoid breast feeding, decrease the risk…
- Trial name
- NCT01625169
- Testing
- Etravirine pharmacokinetics in breast milk and plasma
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Southern California
HIV Infections
Determining Characteristics and Behaviors of Adolescent Women Regarding HIV Risk and Microbicide Trial Participation
This study will examine characteristics and behaviors of young women in India and Tanzania to determine which challenges and opportunities exist for conducting future trials of HIV prevention treatments.
- Trial name
- NCT00872261
- Where
- Tanzania
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- FHI 360
HIV Infections
Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness
The purpose of this study is to determine whether Motivating Youth to Reduce Infections, Disconnections, and Emotion dysregulation (MY-RIDE) decreases substance use , to determine whether MY-RIDE increases human immunodeficiency…
- Trial name
- NCT06074354
- Testing
- Attention-control group, MY-RIDE group
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV-1, HIV Infections
Treatment De-Intensification and Residual HIV-1 in Youth
This laboratory-based sub-study of ATN 061 and ATN 071 will examine the effect of early treatment followed by treatment de-intensification to atazanavir/ritonavir (ATV/r) monotherapy on steady-state frequencies of…
- Trial name
- NCT00867854
- Testing
- Blood draw
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 34 people
- Sponsor
- University of North Carolina, Chapel Hill
Opportunistic Infections, HIV Related, Disseminated Mycobacterium Avium Complex Infection
Enhanced Treatment Strategy for Disseminated MAC Infection in HIV Patients: A Randomized Controlled Trial
Background: Disseminated Mycobacterium avium complex (MAC) infection remains a serious opportunistic infection in patients with advanced HIV infection, particularly among those with severe immunosuppression.
- Trial name
- NCT07585461
- Testing
- Standard Triple Therapy, Experimental: Standard Triple Therapy Plus Fluoroquinolone
- Volunteers
- 124 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in men versus women and in those with versus without HIV infection.
- Trial name
- NCT01386970
- Testing
- zidovudine 300mg and lamivudine 150mg as Combivir
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Acquired Immunodeficiency Syndrome
Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
To investigate the efficacy and tolerability of the regimen of dolutegravir plus lamivudine in HIV infected adults who are virologically suppressed and with evidence of TDF toxicity.
- Trial name
- NCT05493969
- Testing
- Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
- Volunteers
- 100 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV
IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas
The goal of this implementation science study is to learn about the experience of receiving and providing cabotegravir + rilpivirine long-acting (CAB+RPV LA) injections as treatment for human immunodeficiency virus (HIV) for…
- Trial name
- IM-CAPABLE (NCT06451341)
- Testing
- Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), Feasibility of Intervention Measure (FIM)
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Nebraska
Chronic Kidney Disease
Providing Resources to Enhance Patients' Readiness to Make Decisions About Kidney Disease: The PREPARE NOW Study
This study evaluates the effectiveness of patient educational materials (a book and DVD) to help patients with chronic kidney disease make early, shared, and informed decisions about kidney replacement therapy.
- Trial name
- PREPARE NOW (NCT02428569)
- Testing
- PREPARED Decision Support
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
HIV-1 Infection
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
This is a randomized, double-blind, double-dummy, 48-week, comparative study. Approximately 150 HIV-infected, treatment-naïve patients with CCR5-tropic virus will be stratified by HIV-1 RNA: ≥100,000 copies/mL versus <100,000…
- Trial name
- NCT01338883
- Testing
- Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 143 people
- Sponsor
- Tobira Therapeutics, Inc.
HIV
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects.
- Trial name
- NCT02707861
- Testing
- ibalizumab, Optimized Background Regimen
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- TaiMed Biologics Inc.
HIV
Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections
Respiratory infections have a high associated morbidity and mortality, especially in immunocompromised patients. To initiate effective treatment of respiratory infections, it is essential that a rapid and thorough laboratory…
- Trial name
- NCT01212042
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis
To determine whether co-administration of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) improves tolerance to ganciclovir in patients previously intolerant because of neutropenia defined as an absolute…
- Trial name
- NCT00002070
- Testing
- Sargramostim, Ganciclovir
- Where
- 14 sites in United States
- Sponsor
- Schering-Plough
Blood Donors, Blood Transfusion
Transfusion Infections Pediatric Prospective Study (TRIPPS)
To conduct a prospective study of pediatric transfusion recipients to determine the risk of transmitting various infectious agents by blood transfusion.
- Conditions
- Blood Donors, Blood Transfusion, Cytomegalovirus Infections, Hepatitis, Viral, Human
- Trial name
- TRIPPS (NCT00029406)
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Naomi Luban
HIV, AIDS
Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care
To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS.
- Conditions
- HIV, AIDS, Smoking Cessation
- Trial name
- NCT03670316
- Testing
- Algorithm Treatment, Quitline only
- Where
- United States
- Volunteers
- 371 people
- Sponsor
- University of Alabama at Birmingham
HIV Infections
Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy
When an HIV infected person taking strong anti-HIV drugs temporarily stops taking them, viral load rises and the body's immune system is exposed to more HIV.
- Trial name
- NCT00038259
- Testing
- Aldesleukin
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Multi-Component Intervention to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
Engagement in HIV medical care and adherence to HIV medications are both essential in improving health outcomes among people living with HIV (PLH), but PLH living in rural areas-who suffer higher mortality rates than their urban…
- Trial name
- NCT04549259
- Testing
- Group-Based Social Support, HIV Stigma Reduction, Strengths-Based Case Management (SBCM)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Medical College of Wisconsin
HIV
SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
This study aims to investigate whether substitution of Efavirenz (EFV) as the Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) fixed-dose combination (FDC) Atripla, with Rilpivirine as the tenofovir/emtricitabine/rilpivirine…
- Trial name
- NCT02529059
- Testing
- Eviplera
- Where
- 3 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- St Stephens Aids Trust